Halda Therapeutics, a biotech company based in New Haven, CT, has secured $3,050,000,000 in investment capital. This significant funding round will advance the company’s mission to develop novel precision medicines for oncology, particularly its innovative RIPTAC™ therapeutics. The capital injection underscores investor confidence in Halda’s approach to addressing challenging areas in cancer treatment.
Founded by world-renowned Yale scientist Professor Craig Crews, Halda is developing RIPTAC therapeutics as a new drug modality for cancer. This innovative approach is designed to overcome common bypass mechanisms of drug resistance, a significant limitation of many current precision cancer medicines. RIPTAC therapeutics operate using a novel ‘hold and kill’ mechanism, selectively targeting cancer cells by bringing two proteins together. This process leads to the loss of an essential function for cell survival and subsequent cancer cell death, without relying on traditional oncogenic disease drivers.
The newly raised capital is earmarked to further develop Halda’s pipeline of RIPTAC therapeutics for major cancer types. This includes addressing the critical unmet needs of patients with drug-resistant cancers. The funding will also support the continued invention of new medicines using the company’s proprietary platform technology and general growth initiatives, enabling Halda to expand its research and development capabilities.
With this investment, Halda Therapeutics is positioned to accelerate its efforts in drug discovery. The company aims to push the boundaries of scientific innovation to identify and deliver better solutions for cancer patients. Halda operates from its headquarters and state-of-the-art laboratories in New Haven, CT's Science Park, fostering an environment of collaboration, passion, and creativity in its pursuit of groundbreaking cancer treatments.
